Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1990 1
1995 1
1996 1
1997 1
1998 3
1999 2
2000 2
2001 4
2002 3
2003 5
2004 8
2005 3
2006 3
2007 8
2008 13
2009 16
2010 14
2011 23
2012 12
2013 10
2014 11
2015 9
2016 5
2017 9
2018 10
2019 14
2020 9
2021 8
2022 9
2023 12
2024 12
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

213 results

Results by year

Filters applied: . Clear all
Page 1
LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer.
Pérez-Núñez I, Rozalén C, Palomeque JÁ, Sangrador I, Dalmau M, Comerma L, Hernández-Prat A, Casadevall D, Menendez S, Liu DD, Shen M, Berenguer J, Ruiz IR, Peña R, Montañés JC, Albà MM, Bonnin S, Ponomarenko J, Gomis RR, Cejalvo JM, Servitja S, Marzese DM, Morey L, Voorwerk L, Arribas J, Bermejo B, Kok M, Pusztai L, Kang Y, Albanell J, Celià-Terrassa T. Pérez-Núñez I, et al. Among authors: menendez s. Nat Cancer. 2022 Mar;3(3):355-370. doi: 10.1038/s43018-022-00339-4. Epub 2022 Mar 17. Nat Cancer. 2022. PMID: 35301507
NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer.
Santana-Hernández S, Suarez-Olmos J, Servitja S, Berenguer-Molins P, Costa-Garcia M, Comerma L, Rea A, Perera-Bel J, Menendez S, Arpí O, Bermejo B, Martínez MT, Cejalvo JM, Comino-Méndez I, Pascual J, Alba E, López-Botet M, Rojo F, Rovira A, Albanell J, Muntasell A. Santana-Hernández S, et al. Among authors: menendez s. J Exp Clin Cancer Res. 2024 Jan 3;43(1):10. doi: 10.1186/s13046-023-02918-4. J Exp Clin Cancer Res. 2024. PMID: 38167224 Free PMC article.
p53: guardian of reprogramming.
Menendez S, Camus S, Izpisua Belmonte JC. Menendez S, et al. Cell Cycle. 2010 Oct 1;9(19):3887-91. doi: 10.4161/cc.9.19.13301. Epub 2010 Oct 9. Cell Cycle. 2010. PMID: 20948296 Review.
mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer.
Casadevall D, Hernández-Prat A, García-Alonso S, Arpí-Llucià O, Menéndez S, Qin M, Guardia C, Morancho B, Sánchez-Martín FJ, Zazo S, Gavilán E, Sabbaghi MA, Eroles P, Cejalvo JM, Lluch A, Rojo F, Pandiella A, Rovira A, Albanell J. Casadevall D, et al. Among authors: menendez s. Mol Cancer Res. 2022 Jul 6;20(7):1108-1121. doi: 10.1158/1541-7786.MCR-21-0545. Mol Cancer Res. 2022. PMID: 35348729 Free article.
Enhancing immunotherapy through PD-L1 upregulation: the promising combination of anti-PD-L1 plus mTOR inhibitors.
Hernández-Prat A, Rodriguez-Vida A, Cardona L, Qin M, Arpí-Llucià O, Soria-Jiménez L, Menendez S, Quimis FG, Galindo M, Arriola E, Salido M, Juanpere-Rodero N, Rojo F, Muntasell A, Albanell J, Rovira A, Bellmunt J. Hernández-Prat A, et al. Among authors: menendez s. Mol Oncol. 2025 Jan;19(1):151-172. doi: 10.1002/1878-0261.13699. Epub 2024 Sep 11. Mol Oncol. 2025. PMID: 39258533 Free PMC article.
213 results